Carisma Therapeutics Receives FDA Clearance of Investigational New Drug Application for CT-0525, a Novel CAR-M Cell Therapy
Having received a Study May Proceed notification from the FDA, Carisma plans to initiate a Phase 1 study in the months to come and to treat the first patient in the first half of 2024.
Penn’s Leadership Role in Philadelphia’s Rapidly Growing Life Sciences Industry Highlighted
Technical.ly published an article about the future of the growth of the life sciences in Philadelphia, highlighting Penn’s role in the development of the city as a strong tech hub.
Technical.ly State of the Philadelphia Tech Economy Report Highlights Innovation Accomplishments at Penn
According to the report, Penn ranked within the top five largest research & development expenditures of US universities in 2021.
ViTToria Biotherapeutics Secures $15M
ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.
Vivodyne Awarded Multiple Patents and Closed a $38 Million Seed Funding Round
Penn spinout Vivodyne closed a $38 million seed funding round led by Khosla Ventures.
Cabaletta Bio Receives Another FDA Clearance for IND application of CABA-201
The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients with generalized myasthenia gravis (gMG).
Heirloom Opens First Commercial Carbon Capture Plant in the U.S.
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
Vetigenics’ Treats its First Canine Cancer Patient
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.
IND Clearance Achieved by Cabaletta Bio
Cabaletta Bio received FDA clearance for their fourth Investigational New Drug application of CABA-201, their CAR T cell investigational therapy, to treat patients with generalized myasthenia gravis.
Penn spinout Interius Biotherapeutics raises another $21.5M
Co-founded by Saar Gill, MD, PhD, Interius is developing a new platform for cell-specific gene delivery in patients.